Why Is Serina Therapeutics Stock Falling In Pre-market?

(RTTNews) - Serina Therapeutics (SER) announced that the FDA has placed a clinical hold on the Investigational New Drug application for SER-252, Serina's lead development program for advanced Parkinsons disease. The FDA has requested additional information related to a commonly used excipient in the formulation.

Serina said it expects to receive the FDA's formal clinical-hold letter within 30 days and will provide an update once it has aligned with the FDA on next steps and timelines.

Shares of Serina Therapeutics are down 8% in pre-market trade on Monday.

For More Such Health News, visit rttnews.com.